Complete and print.

Reset Form

MAYO CLINIC LABORATORIES

Neurology Specialty Testing
Client Test Request

Client Information (required)

Client Name		
Client Account No.		
Client Phone	Client Order No.	
Street Address		
City	State	ZIP Code

Submitting Provider Information (required)

Submitting/Referring Provider *(Last, First)*

Fill in only if Call Back is required.

Phone (with area code)	Fax (with area code)
Provider's National I.D. (NPI)	

**Fax number given must be from a fax machine that complies with applicable HIPAA regulation.*

"I hereby confirm that informed consent has been signed by an individual legally authorized to do so and is on file with this office or the individual's provider's office."

Signature ▶

Note: It is the client's responsibility to maintain documentation of the order.

Patient Information (required)

Patient ID (Medical Record No.)		
Patient Name *(Last, First, Middle)*		
Sex ☐ Male ☐ Female	Birth Date *(mm-dd-yyyy)*	
Collection Date *(mm-dd-yyyy)*	Time ☐ am ☐ pm	
Street Address		
City	State	ZIP Code
Phone		

Reason for Testing (required)

ICD-10 Diagnosis Code

Note: It is the client's responsibility to maintain documentation of the order.
New York State Patients: Informed Consent for Genetic Testing

MCL Internal Use Only

Ship specimens to:
Mayo Clinic Laboratories
3050 Superior Drive NW
Rochester, MN 55901

Customer Service: 855-516-8404

Visit www.MayoClinicLabs.com for the most up-to-date test and shipping information.

Billing Information
- An itemized invoice will be sent each month.
- Payment terms are net 30 days.

Call the Business Office with billing related questions:
800-447-6424 (US and Canada)
507-266-5490 (outside the US)

T732
MC0767-02Arev0522

Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name *(Last, First, Middle)*	Client Order No.
Birth Date *(mm-dd-yyyy)*	

AUTOIMMUNE CNS AND PARANEOPLASTIC DISORDERS

- ☐ ENS2 — Encephalopathy, Autoimmune/ Paraneoplastic Evaluation, Serum (NMDA, LGI1, CASPR2, AMPA, GABA, DPPX, mGluR1, PCA-Tr, IgLON5, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF)
- ☐ ENC2 — Encephalopathy, Autoimmune/ Paraneoplastic Evaluation, Spinal Fluid (NMDA, LGI1, CASPR2, AMPA, GABA, DPPX, mGluR1, PCA-Tr, IgLON5, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA- 1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF)
- ☐ K11CS — Kelch-Like Protein 11 Antibody, Cell Binding Assay, Serum
- ☐ K11CC — Kelch-Like Protein 11 Antibody, Cell Binding Assay, Spinal Fluid
- ☐ GD65S — Glutamic Acid Decarboxylase (GAD65) Antibody Assay, Serum
- ☐ GD65C — Glutamic Acid Decarboxylase (GAD65) Antibody Assay, Spinal Fluid

Pediatric CNS Disorders

- ☐ PCDEC — Pediatric Autoimmune Encephalopathy/ CNS Disorders Evaluation, Spinal Fluid (NMDA, LGI1, CASPR2, GABA, AQP4, DPPX, MGluR1, PCA-Tr, ANNA-1, GAD65, GFAP)
- ☐ PCDES — Pediatric Autoimmune Encephalopathy/ CNS Disorders Evaluation, Serum (NMDA, LGI1, CASPR2, GABA, AQP4, MOG, DPPX, MGluR1, PCA-Tr, ANNA-1, GAD65, GFAP)

AUTOIMMUNE VISION LOSS

- ☐ PVLE — Paraneoplastic Vision Loss Evaluation, Serum (RCVBS, CRMS)
- ☐ RCVBS — Recoverin-IgG Antibody by Immunoblot, Serum

DEMENTIA

Alzheimer's Disease

- ☐ ADEVL — Alzheimer's Disease Evaluation, Spinal Fluid (Abeta42, total-Tau, p-Tau181, p-Tau181/Abeta42 ratio)
- ☐ APOEG — Apolipoprotein E Genotyping, Blood

Autoimmune Dementia

- ☐ DMS2 — Dementia, Autoimmune/Paraneoplastic Evaluation, Serum (NMDA, LGI1, CASPR2, AMPA, GABA, DPPX, mGluR1, PCA-Tr, IgLON5, ANNA-1, ANNA- 2, ANNA-3, AGNA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF)
- ☐ DMC2 — Dementia, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid (NMDA, LGI1, CASPR2, AMPA, GABA, DPPX, mGluR1, PCA-Tr, IgLON5, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-2, CRMP- 5, Amphiphysin, GAD65, GFAP, NIF)

Creutzfeld Jakob Disease

- ☐ NSESF — Neuron-Specific Enolase (NSE), Spinal Fluid

Frontotemporal Dementia

- ☐ C9ORF — C9orf72 Hexanucleotide Repeat, Molecular Analysis
- ☐ MAPTZ — MAPT Gene, Sequence Analysis, 7 Exon Screening Panel
- ☐ GRNZ — Progranulin Gene (GRN), Full Gene Analysis

CADISIL

- ☐ NTC3Z — NOTCH3 Gene, Full Gene Analysis

DEMYELINATING DISEASE

- ☐ CDS1 — CNS Demyelinating Disease Evaluation, Serum (AQP4, MOG)
- ☐ NMOFS — Neuromyelitis Optica (NMO)/ Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Serum
- ☐ MOGFS — Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Serum
- ☐ KCSF — Immunoglobulin Kappa Free Light Chain, Spinal Fluid
- ☐ MSP3 — Multiple Sclerosis (MS) Profile, Serum and Spinal Fluid

DEVELOPMENTAL DELAY

- ☐ CMACB — Chromosomal Microarray, Congenital, Blood
- ☐ FXS — Fragile X Syndrome, Molecular Analysis
- ☐ PWAS — Prader-Willi/Angelman Syndrome, Molecular Analysis
- ☐ MCP2Z — MECP2 Gene, Full Gene Analysis

DYSAUTONOMIA

- ☐ DYS2 — Dysautonomia Autoimmune/Paraneoplastic Evaluation, Serum (LGI1, CASPR2, DPPX, AChR Ganglionic, ANNA-1, PCA-2, CRMP-5)

EPILEPSY

Autoimmune Epilepsy

- ☐ EPS2 — Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum (NMDA, LGI1, CASPR2, AMPA, GABA, DPPX, mGluR1, PCA-Tr, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP)
- ☐ EPC2 — Epilepsy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid (NMDA, LGI1, CASPR2, AMPA, GABA, DPPX, mGluR1, PCA-Tr, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP)

Hereditary Epilepsy

- ☐ EPPAN — Comprehensive Epilepsy Gene Panel (319 genes)
- ☐ HMEP — Hemiplegic Migraine Gene Panel (9 genes)
- ☐ TSCP — Tuberous Sclerosis Gene Panel (2 genes)
- ☐ CSTB — CSTB Repeat Expansion Analysis
- ☐ CGPH — Custom Gene Panel, Hereditary (This test can be utilized to modify any of the above panels or to order a single gene from any of the above panels.)

Gene List ID: _____

FOLLOW-UP TESTING - NEUROIMMUNOLOGY

- ☐ PNEFS — Neuroimmunology Antibody Follow-up, Serum
  Specify Antibody: _____
- ☐ PNEFC — Neuroimmunology Antibody Follow-up, Spinal Fluid
  Specify Antibody: _____

MENINGITIS

- ☐ CSFME — Meningitis/Encephalitis Pathogen Panel, PCR, Spinal Fluid

HEREDITARY HEARING LOSS

- ☐ HHLP — AudioloGene Hereditary Hearing Loss Panel, Varies

MITOCHONDRIAL DISORDERS

- ☐ GDF15 — Growth Differentiation Factor 15, Plasma
- ☐ MITOP — Mitochondrial Full Genome Analysis by Next-Generation Sequencing (NGS)
- ☐ MITON — Mitochondrial Nuclear Gene Panel by Next-Generation Sequencing (NGS)
- ☐ MITOT — Combined Mitochondrial Analysis, Mitochondrial Full Genome and Nuclear Gene Panel

Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name *(Last, First, Middle)*	Client Order No.
Birth Date *(mm-dd-yyyy)*	

MOVEMENT DISORDERS

Autoimmune Movement Disorders

- ☐ GLYCS — Glycine Receptor Alpha1 IgG, Cell Binding Assay, Serum
- ☐ GLYCC — Glycine Receptor Alpha1 IgG, Cell Binding Assay, Spinal Fluid
- ☐ MDS2 — Movement Disorder, Autoimmune/ Paraneoplastc Evaluation, Serum (NMDA, LGI1, CASPR2, DPPX, MGluR1, VGCC-P/Q, PCA-Tr, IgLON5, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GRAF1, ITPR1, KLHL11, NIF)
- ☐ MDC2 — Movement Disorder, Autoimmune/ Paraneoplastic Evaluation, Spinal Fluid (NMDA, LGI1, CASPR2, DPPX, MGluR1, PCA-Tr, IgLON5, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GRAF1, ITPR1, KLHL11, NIF)
- ☐ SPPS — Stiff-Person Spectrum Disorders Evaluation, including Progressive Encephalomyelitis with Rigidity and Myoclonus, Serum (GlyR, GAD65, DPPX, Amphiphysin)
- ☐ SPPC — Stiff-Person Spectrum Disorders Evaluation, including Progressive Encephalomyelitis with Rigidity and Myoclonus, Spinal Fluid (GlyR, GAD65, DPPX, Amphiphysin)

Hereditary Movement Disorders

- ☐ DRPL — Dentatorubral-Pallidoluysian Atrophy (DRPLA) Gene Analysis
- ☐ FFRWB — Friedreich Ataxia, Frataxin, Quantitative, Whole Blood
- ☐ AFXN — Friedreich Ataxia, Repeat Expansion Analysis
- ☐ HAD — Huntington Disease, Molecular Analysis
- ☐ SCAP — Spinocerebellar Ataxia Repeat Expansion Panel
- ☐ SCARA — Spinocerebellar Ataxia Type 1, 2, 3, 6, or 7, Repeat Expansion Analysis

MYELOPATHY

- ☐ MAS1 — Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum (AQP4, MOG, DPPX, mGluR1, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF)
- ☐ MAC1 — Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid (AQP4, DPPX, mGluR1, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF)

NEURODEGENERATION

- ☐ NFLC — Neurofilament Light Chain, Plasma

NEUROMUSCULAR

Neuromuscular Junction Disorders

- ☐ MGMR — Myasthenia Gravis Evaluation with Muscle-Specific Kinase (MuSK) Reflex, Serum
- ☐ MGLE — Myasthenia Gravis/Lambert-Eaton Myasthenic Syndrome Evaluation, Serum

Stand-Alone Antibodies

- ☐ ARBI — Acetylcholine Receptor (Muscle AChR) Binding Antibody, Serum
- ☐ MUSK — Muscle-Specific Kinase (MuSK) Autoantibody, Serum

Autoimmune Neuromuscular

Immune-Mediated Necrotizing Myopathy

- ☐ NMS1 — Necrotizing Myopathy Evaluation, Serum (HMGCR, SRP)

Hereditary Neuromuscular

Neuromuscular Disorders

- ☐ NMPAN — Neuromuscular Genetic Panels by Next-Generation Sequencing (NGS)

Select one subpanel from the list below.

- ☐ Custom Gene Panel
  Gene List ID: _____

Distal Myopathy + Peripheral Neuropathy

- ☐ Distal Weakness Expanded Panel (217 genes)

Myopathies

- ☐ Myopathy Expanded Panel (141 genes)
- ☐ Muscular Dystrophy Panel (77 genes)
- ☐ Congenital Myopathy Panel (36 genes)
- ☐ Metabolic Myopathy Panel (41 genes)
- ☐ Myofibrillar Myopathy Panel (12 genes)
- ☐ Distal Myopathy Panel (27 genes)
- ☐ Emery-Dreifuss Panel (5 genes)
- ☐ Rhabdomyolysis and Myopathy Panel (31 genes)

Motor Neuron Disease

- ☐ Motor Neuron Disease Panel (17 genes)

Neuromuscular Junction

- ☐ Congenital Myasthenic Syndromes Panel (25 genes)

Hyperexcitable Muscle Disease

- ☐ Skeletal Muscle Channelopathy Panel (6 genes)
- ☐ DBMD — Duchenne/Becker Muscular Dystrophy, DMD Gene, Large Deletion/Duplication Analysis
- ☐ SMNDX — Spinal Muscular Atrophy Diagnostic Assay, Deletion/Duplication Analysis
- ☐ SBULB — Spinal Muscular Atrophy (Kennedy Disease), Molecular Analysis

NEUROPATHY

Autoimmune Neuropathy

Axonal

- ☐ GM1B — Ganglioside Antibody Panel, Serum (Monosialo GM1, IgG; Monosialo GM1, IgM; Asialo GM1, IgG; Asialo GM1, IgM; GD1b, IgG; GD1b, IgM)
- ☐ AIAES — Axonal Neuropathy, Autoimmune/ Paraneoplastic Evaluation, Serum (LGI1, CASPR2, ANNA-1, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin)

Demyelinating

- ☐ GM1B — Ganglioside Antibody Panel, Serum (Monosialo GM1, IgG; Monosialo GM1, IgM; Asialo GM1, IgG; Asialo GM1, IgM; GD1b, IgG; GD1b, IgM)
- ☐ MAGES — Myelin Associated Glycoproteins (MAG) Autoantibodies (IgM), Serum
- ☐ NF4FS — Neurofascin-155 IgG4, Flow Cytometry, Serum

Hereditary Peripheral Neuropathy

- ☐ PMPDD — *PMP22* Gene, Large Deletion/Duplication Analysis
- ☐ NPPAN — Peripheral Neuropathy Genetic Panels by Next-Generation Sequencing (NGS), Blood

Select one subpanel from the list below.

- ☐ Custom Gene Panel
  Gene List ID: _____
- ☐ Hereditary Motor Neuropathy Panel (23 genes)
- ☐ Hereditary Sensory Neuropathy Panel (18 genes)
- ☐ Metabolic or Syndromic Neuropathies (74 genes)
- ☐ Motor and Sensory Neuropathy Panel (82 genes)
- ☐ Peripheral Neuropathy Expanded Panel (193 genes)
- ☐ SEPT9 Gene, Full Gene Analysis (1 gene)
- ☐ Spastic Paraplegia Neuropathy Panel (41 genes)

PARANEOPLASTIC TESTING

- ☐ PAVAL — Paraneoplastic, Autoantibody Evaluation, Serum (VGKC, VGCC-P/Q, PCA-Tr, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin)
- ☐ PAC1 — Paraneoplastic, Autoantibody Evaluation, Spinal Fluid (PCA-Tr, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin)

SLEEP DISORDERS

- ☐ ORXNA — Orexin-A/Hypocretin-1, Spinal Fluid

Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name *(Last, First, Middle)*	Client Order No.
Birth Date *(mm-dd-yyyy)*	

THERAPEUTIC TESTING / DRUG MONITORING

Antiepileptic Drugs

- ☐ AMOBS Amobarbital, Serum
- ☐ CARTA Carbamazepine, Total, Serum
- ☐ CDP Chlordiazepoxide and Metabolite, Serum
- ☐ DIA Diazepam and Nordiazepam, Serum
- ☐ ETX Ethosuximide, Serum
- ☐ FELBA Felbamate (Felbatol), Serum
- ☐ GABA Gabapentin, Serum
- ☐ LACO Lacosamide, Serum
- ☐ LAMO Lamotrigine, Serum
- ☐ LEVE Levetiracetam, Serum
- ☐ OMHC Oxcarbazepine Metabolite, Serum
- ☐ PBR Phenobarbital, Serum
- ☐ PNYA Phenytoin, Total, Serum
- ☐ PRMB Primidone and Phenobarbital, Serum
- ☐ SECOS Secobarbital, Serum
- ☐ TOPI Topiramate, Serum
- ☐ VALPA Valproic Acid, Total, Serum
- ☐ ZONI Zonisamide, Serum

Pharmacogenomics

- ☐ PGXQP Focused Pharmacogenomics Panel (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, SLCO1B1, VKORC1, CYP4F2, and rs12777823)
- ☐ CARBR Carbamazepine Hypersensitivity Pharmacogenomics, Varies
- ☐ COMTQ Catechol-O-Methyltransferase (COMT) Genotype
- ☐ 1A2Q Cytochrome P450 1A2 Genotype
- ☐ 2C19R Cytochrome P450 2C19 Genotype
- ☐ 2C9QT Cytochrome P450 2C9 Genotype
- ☐ 2D6Q Cytochrome P450 2D6 Comprehensive Cascade
- ☐ 3A4Q Cytochrome P450 3A4 Genotype
- ☐ 3A5Q Cytochrome P450 3A5 Genotype
- ☐ NAT2Q N-Acetyltransferase 2 *(NAT2)* Genotype
- ☐ TPNUQ Thiopurine Methyltransferase (TPMT) and Nudix Hydrolase (NUDT15) Genotyping
- ☐ WARSQ Warfarin Response Genotype

ADDITIONAL TESTS (INDICATE TEST NUMBER AND NAME)

Print

T732
MC0767-02Arev0522